Akebia Therapeutics Inc. buy Piper Sandler
Start price
14.03.25
/
50%
€1.97
Target price
14.03.26
€5.53
Performance (%)
-41.46%
Price
23.01.26
€1.15
Summary
This prediction is currently active. The BUY prediction by Piper_Sandler for Akebia Therapeutics Inc. is performing very badly with a performance of -41.46%. This prediction currently runs until 14.03.26. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | 3.085% | 3.085% |
| iShares Core DAX® | -1.764% | 2.259% |
| iShares Nasdaq 100 | -1.632% | -0.193% |
| iShares Nikkei 225® | -2.451% | 4.086% |
| iShares S&P 500 | -2.252% | -0.151% |
Comments by Piper_Sandler for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at Piper Sandler from $4.00 to $6.00. They now have an "overweight" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by Piper_Sandler for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
31.05.23
31.05.23
-
31.05.24
31.05.24
13.76%
01.06.24
01.06.24
